Incorrect biopsy results cloud Nymox Pharma prostate cancer study

Whatsapp News

Nymox Pharmaceutical Corp said its experimental prostate reduced the progression cancer in patients, but it could not determine if the study succeeded in meeting pre-determined goals due a high rate of incorrect biopsies.

In the mid-stage study, patients receiving a single injection of the drug, NX-1207, had less cancer progression in the treated area than in untreated patients.

The main goal of the trial was to show a significantly higher number of patients with undetectable prostate cancer after 45 days of treatment, compared to untreated patients.

However, the was unable to assess the drug’s benefit because of a high percentage of false negative biopsies – a result suggesting there is cancer present when it actually is – in the untreated patients’ group. (Reuters)